^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Aidixi (disitamab vedotin) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）
Excerpt:
...Use pre-treatment endoscopic biopsy samples for HER2 detection in the local laboratory: HER2 high expression confirmed after IHC results (defined as: IHC 2+ 3+); 7....
Source:
Title:
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
Excerpt:
...- HER2 overexpression defined as HER2 IHC 2+ or 3+....
Trial ID:
More C2 evidence
Source:
Title:
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
Excerpt:
...- HER2 overexpression defined as HER2 IHC 2+ or 3+....
Trial ID:
Less C2 evidence
Source:
Title:
Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.
Published date:
05/19/2021
Excerpt:
...9 (30%) harbored HER2 mutation/overexpression (received RC48-ADC or trastuzumab, cohort B)…In cohort B, ORR was 44% (4/9), DCR was 78% (7/9), mPFS and mOS was 3.1 months and 5.5 months, respectively.
Source:
Title:
A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.
Published date:
05/13/2020
Excerpt:
RC48-ADC demonstrated a clinically meaningful response and survival benefit in the heavily treated patients with HER2-overexpressing gastric or gastro-esophageal junction cancers.
DOI:
10.1200/JCO.2020.38.15_suppl.4560
Trial ID:
